188 related articles for article (PubMed ID: 29660019)
1. Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.
Linninger A; Hartung GA; Liu BP; Mirkov S; Tangen K; Lukas RV; Unruh D; James CD; Sarkaria JN; Horbinski C
Neuro Oncol; 2018 Aug; 20(9):1197-1206. PubMed ID: 29660019
[TBL] [Abstract][Full Text] [Related]
2. In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma.
Khurshed M; Molenaar RJ; Lenting K; Leenders WP; van Noorden CJF
Oncotarget; 2017 Jul; 8(30):49165-49177. PubMed ID: 28467784
[TBL] [Abstract][Full Text] [Related]
3. Mutant IDH1 and seizures in patients with glioma.
Chen H; Judkins J; Thomas C; Wu M; Khoury L; Benjamin CG; Pacione D; Golfinos JG; Kumthekar P; Ghamsari F; Chen L; Lein P; Chetkovich DM; Snuderl M; Horbinski C
Neurology; 2017 May; 88(19):1805-1813. PubMed ID: 28404805
[TBL] [Abstract][Full Text] [Related]
4. Isocitrate dehydrogenase mutations in gliomas.
Waitkus MS; Diplas BH; Yan H
Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
[TBL] [Abstract][Full Text] [Related]
5. MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.
Molloy AR; Najac C; Viswanath P; Lakhani A; Subramani E; Batsios G; Radoul M; Gillespie AM; Pieper RO; Ronen SM
Theranostics; 2020; 10(19):8757-8770. PubMed ID: 32754276
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
[TBL] [Abstract][Full Text] [Related]
7. Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways.
Fack F; Tardito S; Hochart G; Oudin A; Zheng L; Fritah S; Golebiewska A; Nazarov PV; Bernard A; Hau AC; Keunen O; Leenders W; Lund-Johansen M; Stauber J; Gottlieb E; Bjerkvig R; Niclou SP
EMBO Mol Med; 2017 Dec; 9(12):1681-1695. PubMed ID: 29054837
[TBL] [Abstract][Full Text] [Related]
8. Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Balss J; Pusch S; Beck AC; Herold-Mende C; Krämer A; Thiede C; Buckel W; Langhans CD; Okun JG; von Deimling A
Acta Neuropathol; 2012 Dec; 124(6):883-91. PubMed ID: 23117877
[TBL] [Abstract][Full Text] [Related]
9. IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma.
Chen X; Liu J; Li Y; Zeng Y; Wang F; Cheng Z; Duan H; Pan G; Yang S; Chen Y; Li Q; Shen X; Li Y; Qin Z; Chen J; Huang Y; Wang X; Lu Y; Shu M; Zhang Y; Wang G; Li K; Lin X; Xing F; Zhang H
Nat Commun; 2023 Oct; 14(1):6781. PubMed ID: 37880243
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.
Avellaneda Matteo D; Grunseth AJ; Gonzalez ER; Anselmo SL; Kennedy MA; Moman P; Scott DA; Hoang A; Sohl CD
J Biol Chem; 2017 May; 292(19):7971-7983. PubMed ID: 28330869
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.
Juratli TA; Peitzsch M; Geiger K; Schackert G; Eisenhofer G; Krex D
Neuro Oncol; 2013 Jun; 15(6):682-90. PubMed ID: 23410661
[TBL] [Abstract][Full Text] [Related]
12. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.
Sasaki M; Knobbe CB; Itsumi M; Elia AJ; Harris IS; Chio II; Cairns RA; McCracken S; Wakeham A; Haight J; Ten AY; Snow B; Ueda T; Inoue S; Yamamoto K; Ko M; Rao A; Yen KE; Su SM; Mak TW
Genes Dev; 2012 Sep; 26(18):2038-49. PubMed ID: 22925884
[TBL] [Abstract][Full Text] [Related]
13. Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas.
Ohno M; Hayashi Y; Aikawa H; Hayashi M; Miyakita Y; Takahashi M; Matsushita Y; Yoshida A; Satomi K; Ichimura K; Hamada A; Narita Y
Neurology; 2021 Nov; 97(21):e2114-e2123. PubMed ID: 34610989
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
[TBL] [Abstract][Full Text] [Related]
15. Minimally Invasive Detection of IDH1 Mutation With Cell-Free Circulating Tumor DNA and D-2-Hydroxyglutarate, D/L-2-Hydroxyglutarate Ratio in Gliomas.
Tuna G; Dal-Bekar NE; Akay A; Rükşen M; İşlekel S; İşlekel GH
J Neuropathol Exp Neurol; 2022 Jun; 81(7):502-510. PubMed ID: 35582888
[TBL] [Abstract][Full Text] [Related]
16. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.
Pusch S; Schweizer L; Beck AC; Lehmler JM; Weissert S; Balss J; Miller AK; von Deimling A
Acta Neuropathol Commun; 2014 Feb; 2():19. PubMed ID: 24529257
[TBL] [Abstract][Full Text] [Related]
17. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
[TBL] [Abstract][Full Text] [Related]
18. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
Lazovic J; Soto H; Piccioni D; Lou JR; Li S; Mirsadraei L; Yong W; Prins R; Liau LM; Ellingson BM; Cloughesy TF; Lai A; Pope WB
Neuro Oncol; 2012 Dec; 14(12):1465-72. PubMed ID: 23090985
[TBL] [Abstract][Full Text] [Related]
19. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
Jin G; Reitman ZJ; Duncan CG; Spasojevic I; Gooden DM; Rasheed BA; Yang R; Lopez GY; He Y; McLendon RE; Bigner DD; Yan H
Cancer Res; 2013 Jan; 73(2):496-501. PubMed ID: 23204232
[TBL] [Abstract][Full Text] [Related]
20. Nuclear FABP7 regulates cell proliferation of wild-type IDH1 glioma through caveolae formation.
Kagawa Y; Umaru BA; Kanamori M; Zama R; Shil SK; Miyazaki H; Kobayashi S; Wannakul T; Yang S; Tominaga T; Owada Y
Mol Oncol; 2022 Jan; 16(1):289-306. PubMed ID: 34716958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]